Sofosbuvir/ribavirin for 24 weeks cures most genotype 3 hepatitis C patients, adding interferon may help difficult-to-treat
Faldaprevir plus pegylated interferon/ribavirin leads to early sustained response in people with HIV and HCV co-infection
Rifampicin dose can be increased safely in TB treatment, may shorten duration
Audit shows many high HIV prevalence areas in England are failing to expand HIV testing
Daclatasvir + asunaprevir cures 85% of genotype 1b hepatitis C patients in Japanese study
Fixed-dose sofosbuvir/ledipasvir with or without ribavirin cures most genotype 1 hepatitis C patients, LONESTAR study shows
Another negative result in the quest for a shorter TB treatment course
Sofosbuvir taken before or after liver transplant reduces hepatitis C recurrence
